AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

regulatory-affairs-head

Use for medical device market access strategy: FDA 510(k), De Novo or PMA packages, CE marking under MDR, pre-sub meetings, agency deficiency responses or multi-market plans. Analyzes pathways with regulatory_pathway_analyzer.py and tracks submissions with regulatory_tracker.py.

Original source
alirezarezvani
License
MIT
Pinned revision
e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read alirezarezvani--regulatory-affairs-head at revision e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 5

references/eu-mdr-submission-guide.md

EU MDR 2017/745 Submission Guide

MDR Classification and Conformity Assessment Routes

Class I Devices

  • Self-certification under Annex II
  • Technical documentation requirements per Annex II
  • Declaration of Conformity mandatory
  • UDI registration required

Class IIa Devices

  • Notified Body involvement for Annex III Module C2 + Annex V
  • Quality management system assessment
  • Technical documentation review
  • Ongoing surveillance requirements

Class IIb Devices

  • Notified Body certification under Annex III Module B + C or D
  • Type examination or Full quality assurance route
  • Design examination requirements
  • Production surveillance obligations

Class III Devices

  • Comprehensive Notified Body assessment
  • Type examination + production surveillance OR
  • Full quality assurance system approach
  • Design dossier requirements per Annex II

Key MDR Submission Requirements

1. Technical Documentation (Annex II)

  • Device description and intended purpose
  • Risk management documentation (ISO 14971)
  • Clinical evidence per Annex XIV
  • Post-market surveillance plan
  • Performance evaluation reports

2. Quality Management System (Annex I, Chapter II)

  • ISO 13485 compliant QMS
  • Design controls implementation
  • Risk management integration
  • Clinical evaluation procedures
  • Post-market surveillance system

3. Clinical Evidence Requirements

  • Clinical evaluation plan per Annex XIV
  • Literature review and gap analysis
  • Clinical investigation if required
  • Post-market clinical follow-up plan
  • Clinical evaluation report updating

4. UDI System Implementation

  • UDI-DI assignment and registration
  • UDI-PI requirements for higher risk devices
  • EUDAMED registration obligations
  • Labeling compliance with UDI requirements

Submission Timeline Framework

Pre-Submission Phase (6-12 months)

  1. Gap analysis against MDR requirements
  2. Classification confirmation with regulatory experts
  3. Notified Body selection and preliminary discussions
  4. Clinical evidence strategy development
  5. UDI strategy and EUDAMED preparation

Submission Preparation (3-6 months)

  1. Technical documentation compilation
  2. QMS documentation review and update
  3. Clinical evaluation completion
  4. Risk management file finalization
  5. Notified Body application submission

Review and Certification (6-18 months)

  1. Initial assessment by Notified Body
  2. Questions and clarifications response
  3. Audit activities coordination
  4. Certificate issuance and market access
  5. Post-market obligations activation

Critical Success Factors

  • Early engagement with chosen Notified Body
  • Robust clinical evidence strategy and execution
  • Comprehensive risk management throughout lifecycle
  • Proactive post-market surveillance system
  • Regular monitoring of regulatory updates and guidance

Common Pitfalls to Avoid

  • Insufficient clinical evidence planning
  • Late Notified Body engagement
  • Inadequate post-market surveillance systems
  • Poor documentation quality and traceability
  • Underestimating timeline and resource requirements